Nervous System Home > Info on Orally Disintegrating Carbidopa-Levodopa

The U.S. Food and Drug Administration has approved orally disintegrating carbidopa-levodopa (Parcopa®) for Parkinson's disease as well as Parkinson-like symptoms due to:
  • Manganese poisoning
  • Encephalitis
  • Carbon monoxide poisoning.
These tablets are especially designed to dissolve rapidly on the tongue, without the need for water. This is particularly beneficial for people who have trouble swallowing tablets, which is often the case with Parkinson's disease.
Prior to beginning treatment with this drug, review the drug's safety info with your healthcare provider. Orally disintegrating carbidopa-levodopa is not right for everyone. For example, those with malignant melanoma, a history of stomach or intestinal ulcers, or any lung problems may need to consider an alternative form of treatment.
(Click Orally Disintegrating Carbidopa-Levodopa for more information on this drug, including how it works, possible side effects, what to do in cases of overdose, and more.)
Written by/reviewed by:
Last reviewed by: Arthur Schoenstadt, MD
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation




Related Channels

eMedTV Links
Copyright © 2006-2018 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.